Company intelligence / Profile preview

R1 Therapeutics

Boulder, Colorado, United States

Ownership: Private
Development stage: Other

Overview

R1 Therapeutics is developing a best-in-class recombinant Human C1 Esterase Inhibitor (rhC1-INH) for the treatment of Hereditary Angioedema (HAE). Their lead candidate, R1-001, is designed for high-concentration subcutaneous delivery with a significantly longer half-life than current recombinant options, aiming to provide a more convenient and effective prophylactic treatment.

Therapeutic areas: Immunology
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on R1 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R1 Therapeutics.

Explore the full profile